Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis

Table 2 Use of first-line treatment n (%)

	First-line									All newly treated patients
	SSA	CC	TT	SSA + CC	SSA + TT	TT + CC	IF	SSA + IF	SSA + TT + CC
n	1345	752	81	42	31	3	2	1	1	2258
	59.6%	33.3%	3.6%	1.9%	1.4%	0.1%	0.1%	0.0%	0.0%	100.0%
Duration of first-line treatment (mean ± SD, d)	449 ± 434.2	215 ± 228.8	267 ± 325.7	408 ± 327.9	276 ± 189.5	208 ± 165.6	251 ± 285.0	836 ± 0	426 ± 0	361 ± 385.0
First-line ending status	635 (47.2)	609 (81.0)	44 (54.3)	26 (61.9)	14 (45.2)	1 (33.3)	1 (50.0)	0 (0)	1 (100.0)	1331 (58.9)
Stop
Switch	128 (9.5)	33 (4.4)	14 (17.3)	5 (11.9)	7 (22.6)	1 (33.3)	1 (50.0)	0 (0)	0 (0)	189 (8.4)
End of enrollment	582 (43.3)	110 (14.6)	23 (28.4)	11 (26.2)	10 (32.3)	1 (33.3)	0 (0)	1 (100.0)	0 (0)	738 (32.7)
Liver directed therapy timing
During first-line	171 (12.7)	87 (11.6)	9 (11.1)	10 (23.8)	4 (12.9)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	282 (12.5)
After first-line	36 (2.7)	39 (5.2)	7 (8.6)	0 (0.0)	2 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	84 (3.7)
+/- 30 d after stopping first line therapy1	635	609	44	26	14	1	1	0	1	1331
	29 (4.6)	42 (6.9)	2 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	73 (5.5)

¹Among patients who stopped.